A new effort in the US Congress to enact a “wildcard” patent incentive to encourage antibiotic development would require companies who sell the exclusivity to contribute 5% of the proceeds to support early-stage antimicrobial research through the Foundation of the National Institutes of Health.
Reps. John Shimkus (R-Ill.) and Tony Cardenas (D-Calif.) plan to offer the “Revaluing Antimicrobial Products Act of 2018” (REVAMP)...







